Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 2/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | CALM1 | P0DP23 | 3/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17016948 | 0.89 | RARB (0.39) | S1PR1FFAR1PPARGPPARDPPARA | |
| SCHEMBL17021092 | 0.89 | RARB (0.39) | S1PR1FFAR1PPARGPPARDPPARA | |
| SCHEMBL17016830 | 0.85 | KMT2A (0.33) | MTNR1BMTNR1ACALM1MEN1KMT2A | |
| SCHEMBL17016853 | 0.82 | RXRG (0.43) | MTNR1BMTNR1ACALM1FFAR1PPARG | |
| SCHEMBL17020997 | 0.82 | RXRG (0.43) | MTNR1BMTNR1ACALM1FFAR1PPARG | |
| SCHEMBL17016942 | 0.80 | FFAR4 (0.35) | CALM1S1PR1FFAR1PPARDPPARA | |
| SCHEMBL17021137 | 0.80 | FFAR4 (0.35) | CALM1S1PR1FFAR1PPARDPPARA | |
| SCHEMBL17016810 | 0.79 | CTSS (0.40) | MTNR1BMTNR1A | |
| SCHEMBL17016949 | 0.79 | RARB (0.39) | CALM1S1PR1PPARDPPARA | |
| SCHEMBL17016967 | 0.76 | RARB (0.33) | S1PR1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9404040-B2 | Liquid crystal compound having fluorine-containing alkenyl terminal group, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150232759-A1 | Liquid crystal compound having fluorine-containing alkenyl terminal group, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232759-A1 | Liquid crystal compound having fluorine-containing alkenyl terminal group, liquid crystal composition and liquid crystal display device | PYM1, CXCR1, LEO1 | MTNR1B 4024/4885MTNR1A 3837/4885CALM1 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.